Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is a commercial-stage biotechnology company with a strong pipeline of innovative protein and small-molecule therapeutics targeting complement-mediated diseases, cancers, and addictive or compulsive disorders. The recent launch of YARTEMLEA, the first and only approved MASP-2 inhibitor, for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), has exceeded expectations and provided early evidence of strong institutional traction and demand. This, along with potential future milestones from the NVO partnership, leads analysts to believe in a favorable risk-reward outlook for Omeros from current levels. Additionally, the company's mechanistic differentiation and favorable safety profile compared to terminal C5 inhibitors could also drive commercial preference from transplant centers.

Bears say

Omeros is facing setbacks with their EU approval, causing them to lower their price target and remove Europe from their plans. Despite this setback, Omeros has potential with their upcoming YARTEMLEA launch and partnership with NVO, making them a viable option for investors. However, the success of AZN's ravulizumab in the same market may pose a threat to Omeros, as it could potentially change real-world transplant-center behavior after YARTEMLEA has secured approval and established experience.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Jul 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.